Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization

This article was originally published in The Pink Sheet Daily

Executive Summary

Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.

You may also be interested in...



Sucampo Re-Embraces Amitiza Through Co-Promote Option After Rescula Falters

While the company had been hopeful about diversifying its revenue base with the launch of its glaucoma drug Rescula, those hopes have faltered and pushed Sucampo to try to maximize the potential behind its main sales-driver, the constipation treatment Amitiza.

Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge

U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel